Show simple item record

dc.contributor.authorYi, Hee
dc.contributor.authorCho, Hee-Jung
dc.contributor.authorCho, Soo-Min
dc.contributor.authorLee, Dong-Goo
dc.contributor.authorAbd El-Aty, AM
dc.contributor.authorYoon, So-Jeong
dc.contributor.authorBae, Gun-Won
dc.contributor.authorNho, Kwang
dc.contributor.authorKim, Bokyung
dc.contributor.authorLee, Chi-Ho
dc.contributor.authorKim, Jin-Suk
dc.contributor.authorBartlett, Michael G
dc.contributor.authorShin, Ho-Chul
dc.date.accessioned2013-06-12T15:05:08Z
dc.date.available2013-06-12T15:05:08Z
dc.date.issued2010-05-18
dc.identifier.citationBMC Cancer. 2010 May 18;10(1):211
dc.identifier.urihttp://dx.doi.org/10.1186/1471-2407-10-211
dc.identifier.urihttp://hdl.handle.net/10724/19683
dc.description.abstractAbstract Background We have studied the in vitro and in vivo utility of polyethylene glycol (PEG)-hydrogels for the development of an anticancer drug 5-fluorouracil (5-FU) delivery system. Methods A 5-FU-loaded PEG-hydrogel was implanted subcutaneously to evaluate the drug retention time and the anticancer effect. For the pharmacokinetic study, two groups of male rats were administered either an aqueous solution of 5-FU (control group)/or a 5-FU-loaded PEG-hydrogel (treated group) at a dose of 100 mg/kg. For the pharmacodynamic study, a human non-small-cell lung adenocarcinoma (NSCLC) cell line, A549 was inoculated to male nude mice with a cell density of 3 × 106. Once tumors start growing, the mice were injected with 5-FU/or 5-FU-loaded PEG-hydrogel once a week for 4 weeks. The growth of the tumors was monitored by measuring the tumor volume and calculating the tumor inhibition rate (IR) over the duration of the study. Results In the pharmacokinetic study, the 5-FU-loaded PEG-hydrogel gave a mean residence time (MRT) of 8.0 h and the elimination half-life of 0.9 h; these values were 14- and 6-fold, respectively, longer than those for the free solution of 5-FU (p < 0.05). In the pharmacodynamic study, A549 tumor growth was significantly inhibited in the 5-FU-loaded PEG-hydrogel group in comparison to the untreated group beginning on Day 14 (p < 0.05-0.01). Moreover, the 5-FU-loaded PEG-hydrogel group had a significantly enhanced tumor IR (p < 0.05) compared to the free 5-FU drug treatment group. Conclusion We suggest that 5-FU-loaded PEG-hydrogels could provide a useful tool for the development of an anticancer drug delivery system.
dc.titlePharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel
dc.typeJournal Article
dc.date.updated2013-06-07T17:14:03Z
dc.description.versionPeer Reviewed
dc.language.rfc3066en
dc.rights.holderHee Yi et al.; licensee BioMed Central Ltd.


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record